An AML patient surface immunophenotype is relatively cost-effective to characterize, raising the prospect of individualized therapy based on a selection of available MAbs. Most certainly, we are entering a new and exciting era in the struggle to improve outcome in adult AML.
Thursday, November 19, 2009
Targeting of AML-leukemic SC with monoclonal antibodies
Targeting of AML-leukemic stem cells with monoclonal antibodies by Erwin M Lee and Richard B Lock, Future Oncol 2009(Nov); 5(9): 1327-30 [PubMed Citation][FriendFeed entry][Full text PDF]. Final sentence of the full text of this Editorial: